Gastrointestinal outcomes and confounders in cystic fibrosis.
about
Pancreatic enzyme replacement therapy for people with cystic fibrosisDefective goblet cell exocytosis contributes to murine cystic fibrosis-associated intestinal disease.Calprotectin in cystic fibrosis.β1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases Sphingosine, Promoting Bacterial InfectionsStudy design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis.Different strategies for reducing intestinal background radioactivity associated with imaging HSV1-tk expression using established radionucleoside probes.Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass.Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis.Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology.Impaired mucosal barrier function in the small intestine of the cystic fibrosis mouse.Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency.Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathwaysCoefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis.Pancreatic and biliary secretion are both altered in cystic fibrosis pigs.Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis.Cystic fibrosis: a model system for precision medicine.The cystic fibrosis intestine.Enteric circular muscle dysfunction in the cystic fibrosis mouse small intestine.Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis.The serological evidence in humans supports a negligible risk of zoonotic infection from porcine circovirus type 2.A novel gene delivery method transduces porcine pancreatic duct epithelial cells.Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP).Nutritional considerations in patients with cystic fibrosis.Lipids in cystic fibrosis.Malnutrition in cystic fibrosis: a review.Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications.Beyond pancreatic insufficiency and liver disease in cystic fibrosis.Gastrointestinal transit times and motility in patients with cystic fibrosis.Guanylate cyclase C reduces invasion of intestinal epithelial cells by bacterial pathogens.DEVELOPMENT OF A POLARIZED PANCREATIC DUCTULAR CELL EPITHELIA FOR PHYSIOLOGICAL STUDIES.Cftr Modulates Wnt/β-Catenin Signaling and Stem Cell Proliferation in Murine Intestine.The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients
P2860
Q24239886-980FA1E1-465B-454D-859A-C64DA16AF6DAQ30628431-512B08E8-72DC-4765-901B-065AC90F397AQ33722951-7FE27F2C-1C1C-42C4-89EC-AC86A9887BACQ33811046-D411FB23-F25D-4555-9A0B-63BBED6637D9Q34040502-C5A560DF-D75C-4E0A-ABAA-C692B42EAC49Q34149294-C73D843E-C982-4CF4-AC10-E2C53E65CC7CQ34747815-774CE71B-20C9-4B8A-8F15-0C7DDFBD3B93Q34994393-A848D231-E307-4AF8-8AC4-DC8DE0E53635Q35136628-86925152-D129-424D-91E2-A76D3E6EDE70Q35148967-D18BF1D2-92BD-4E7D-A187-5D3294C5A7C3Q35178642-188A6558-523D-4A38-962E-08C3A6AC5AB7Q35281958-D9B3A655-1C09-482A-9DA7-DE8C2F27CB47Q35801062-C0E2FE00-7B9A-4255-B8B1-E8AE5E218334Q35832811-A8F7D07A-18C7-4F5D-8F2A-9D831F5033D3Q36131548-D13EC5FD-F289-48BA-9E75-86FBFB0549CBQ36291061-72A960C8-54F3-4BBC-855D-E36EB1BC3A28Q36312709-50265BE7-C456-417F-B1A8-F04BF40214A6Q37052832-8B105B93-885F-4008-AC83-3C2EF269604DQ37097931-4408AE4B-9FD5-4AE8-8701-C93E6B05B6D6Q37122355-27B8ECD2-F2DE-4ADD-A70D-BA89905DD480Q37130749-203776B0-068B-4408-A46C-05364B0E5B4FQ37206368-C6136943-670B-4502-80BF-018E601ECC2CQ37337197-09E732A6-F2C6-47DC-BEF5-40409A922342Q37624228-3D727B7F-6F93-47CD-9D3B-42EA71E5BC76Q37728233-0743B54D-2C08-48E0-8713-3850AD2801D7Q37729993-56C1A82A-00C8-48F4-A693-A559DE332C58Q37920895-E4547A42-B8FE-4539-BA2A-B9F495E61AF2Q38156392-1730FB52-A719-4427-A288-BC65BCD0255AQ38317967-C042AC64-1F2D-4B91-9775-1C0680C24286Q38800967-FA074644-E3D9-4D11-B933-0D060968F1AAQ43346093-AB3730B5-B980-4FF6-B208-3141E043415CQ47701834-90786F27-489D-498F-B23C-262799B31E9CQ51735360-68A06833-8D15-4256-9C90-83611B33B9F5Q55252670-50827EB3-403D-4939-BD8F-C111E1EF9C9CQ57521925-29E28E04-324B-48AD-9F72-3D655A6A1EBE
P2860
Gastrointestinal outcomes and confounders in cystic fibrosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Gastrointestinal outcomes and confounders in cystic fibrosis.
@ast
Gastrointestinal outcomes and confounders in cystic fibrosis.
@en
type
label
Gastrointestinal outcomes and confounders in cystic fibrosis.
@ast
Gastrointestinal outcomes and confounders in cystic fibrosis.
@en
prefLabel
Gastrointestinal outcomes and confounders in cystic fibrosis.
@ast
Gastrointestinal outcomes and confounders in cystic fibrosis.
@en
P2093
P1476
Gastrointestinal outcomes and confounders in cystic fibrosis.
@en
P2093
Christopher J Taylor
Drucy Borowitz
Henkjan J Verkade
James Heubi
John Semler
Lane L Clarke
Maarten Sinaasappel
Mark E Lowe
Morteza Janghorbani
Peter Lewindon
P304
P356
10.1097/01.MPG.0000178439.64675.8D
P407
P577
2005-09-01T00:00:00Z